GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2021-12-02|

Atara Biotherapeutics’ First-In-Class Allogeneic T-Cell Therapy Accepted for EMA Review

by Daniel Ojeda
Share To

T cell therapies have become a powerful tool against a wide range of hematological cancers. Additionally, progress is being made in using them against solid tumors. However, the production of traditional T cell therapies is slow since the patient’s T cells are used to create the therapy. Currently, there is a race to develop allogeneic T cell therapies. These are off-the-shelf therapies that are created using donor’s T cells, allowing therapies to be ready use.

Atara Biotherapeutics has taken the lead after the European Medicines Agency (EMA) agreed to evaluate Tab-cel, their investigational therapy against a rare Epstein-Barr virus-positive cancer. With this, Tab-cel becomes the first-ever off-the-shelf allogeneic T-cell therapy to be reviewed by any regulatory agency in the world.

 

About Atara 

 

Atara uses the T cells from donors that specifically target EBV-infected cells. These serve as the basis for their pipeline of investigational therapies for cancers and autoimmune diseases. Additionally, Atara is developing the next generation of their EBV T cell therapies by combining them with chimeric antigen receptor (CAR) technologies.

The California-based biotherapeutic company currently has three therapies in clinical trials. Their most advanced product is Tab-cel, which is currently under review by EMA for the treatment of EBV-associated post-transplant lymphoproliferative disease. Additionally, three ongoing clinical trials are evaluating Tab-cel as a therapy for several EBV+ cancers. 

“EBV+ PTLD is a rare and aggressive cancer where the patients we seek to treat only have weeks to a few months survival after treatment failure, with no approved options,” said Jakob Dupont, MD, Executive Vice President and Global Head of Research and Development at Atara.

Atara’s pipeline includes ATA188, an investigational treatment for multiple sclerosis, and ATA2271, currently in Phase clinical trials for the treatment of mesothelioma and other solid tumors.

 

First off-the-shelf allogeneic T-cell therapy to be reviewed by any regulatory agency

 

On November 30, Tab-cel made history after EMA fully validated the Marketing Authorization Application (MAA) for the product. Next, the application will be evaluated by the Committee for Medicinal Products for Human Use. The approval decision is expected in the second half of 2022. 

The MAA application includes positive data from the ongoing Phase 3 ALLELE study. Data from this study shows Tab-cel had a 50% objective response rate. Ataria will present findings from the ALLELE study at an upcoming scientific conference. 

Jakob Dupont, MD said “Tab-cel is the first-ever off-the-shelf allogeneic T-cell therapy to be reviewed by a regulatory agency and is a watershed moment for the field and for patients with significant unmet need. We look forward to working with the EMA as the agency evaluates the transformative potential of tab-cel.”

In October 2021, Atara inked an agreement with Pierre Fabre worth up to $365 million to commercialize Tab-cel. Under the agreement, Pierre Fabre will lead the commercialization of Tab-cel in Europe, Middle East, Africa, and other select emerging markets. Atara retains full rights to Tab-cel in North America, Asia Pacific, and Latin America. Additionally, Pierre Fabre will pay Atara to manufacture Tab-cel, and Atara will receive double-digit royalties of net sales.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Major Win – FDA Grants Fast Track Designation to Adicet Bio’s ADI-001 for Lupus Disease
2025-02-07
JPM 2025 Looks at the Cell and Gene Therapy Landscape – Autoimmune, Cancer, and Chronic Diseases are Front and Center
2025-01-21
Cecile Richards’s Battle with Glioblastoma
2025-01-21
LATEST
Novo Nordisk Bets Big on CagriSema With A Heavyweight Move Planned for 2026
2025-02-07
Major Win – FDA Grants Fast Track Designation to Adicet Bio’s ADI-001 for Lupus Disease
2025-02-07
First-of-its-Kind Diagnostic Aid Uses a Single Hair Strand to Detect Autism Risk in Babies
2025-02-06
Teladoc Dials Up Virtual Care with $70 Million Acquisition of Catapult
2025-02-06
Silicon Valley in the Crosshairs as EU Readies to Strike U.S. Big Tech
2025-02-06
Johnson & Johnson Under Fire Again as Legal Action Over Alleged Talc-Cancer Link Moves to the UK
2025-02-05
MediBuddy Partners with Japan’s ELECOM to Launch Smart Health IoT Devices in India
2025-02-05
EVENT
2025-02-05
Precision Medicine World Conference 2025
Santa Clara, California
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top